Indications and uses
Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
hydrALAZINE Hydrochloride Injection, USP
- Manufacturer
- Meitheal Pharmaceuticals Inc. | Kindos Pharmaceuticals Co., Ltd.
- Effective date
- 2026-02-27
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 4
- Source
- full-release
- Hydrated at
- 2026-05-31 22:10:08
Label at a glance#
ProductHYDRALAZINE HYDROCHLORIDE
Active ingredientHydralazine Hydrochloride
Label structure12 sections
Dosage and administration
When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein. Hydralazine hydrochloride injection should be used only when the drug cannot be given orally. The usual dose is 20 to 40 mg, repeated as necessary. Certain patients (especially those with marked renal damage) may require a lower dose. Blood pressure shoul...
Contacts and useful links#
Websitewww.fda.gov
www.fda.gov/medwatch
www.fda.gov/medwatchLabel contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
(For Intramuscular or Intravenous Use)
meitheal®
Rx only
DESCRIPTION
Hydralazine Hydrochloride Injection, USP is an antihypertensive available in a 1 mL vial for intravenous and
intramuscular administration. Hydralazine Hydrochloride Injection, USP is a sterile, nonpyrogenic colorless solution.
Each mL contains:
Active: Hydralazine Hydrochloride, USP, 20 mg
Preservatives: Methylparaben, NF, 0.65 mg; Propylparaben, NF, 0.35 mg
Inactives: Propylene Glycol, USP, 103.6 mg; Sodium Hydroxide and/or Hydrochloric Acid to adjust pH (3.4 to 4.4)
and Water for Injection.
Hydralazine Hydrochloride, USP is 1-hydrazinophthalazine monohydrochloride, and its structural formula is:
Molecular Formula C8H8N4•HCl
Hydralazine Hydrochloride, USP is a white to off-white, odorless crystalline powder. It is soluble in water, slightly
soluble in alcohol, and very slightly soluble in ether. It melts at about 275°C, with decomposition, and has a molecular
weight of 196.64.
CLINICAL PHARMACOLOGY
SPL UNCLASSIFIED SECTION
SPL UNCLASSIFIED SECTION
Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the
cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect
through a direct relaxation of vascular smooth muscle. Hydralazine, by altering cellular calcium metabolism, interferes
with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the
contractile state.
The peripheral vasodilating effect of hydralazine results in decreased arterial blood pressure (diastolic more than
systolic), decreased peripheral vascular resistance, and an increased heart rate, stroke volume and cardiac output.
The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the
increase in cardiac output. Hydralazine usually increases renin activity in plasma, presumably as a result of increased
secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in
renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent
sodium reabsorption. Hydralazine also maintains or increases renal and cerebral blood flow.
The average maximal decrease in blood pressure usually occurs 10 to 80 minutes after administration of hydralazine
hydrochloride injection. No other pharmacokinetic data on hydralazine hydrochloride injection are available.
INDICATIONS AND USAGE
Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
CONTRAINDICATIONS
Hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.
WARNINGS
In a few patients hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests).
PRECAUTIONS
GENERAL PRECAUTIONS SECTION
General
Myocardial stimulation produced by hydralazine can cause anginal attacks and ECG changes of myocardial ischemia. The drug has been implicated in the production of myocardial infarction. It must, therefore, be used with caution in patients with suspected coronary artery disease.
The “hyperdynamic” circulation caused by hydralazine may accentuate specific cardiovascular inadequacies. For example, hydralazine may increase pulmonary artery pressure in patients with mitral valvular disease. The drug may reduce the pressor responses to epinephrine. Postural hypotension may result from hydralazine but is less common than with ganglionic blocking agents. It should be used with caution in patients with cerebral vascular accidents.
In hypertensive patients with normal kidneys who are treated with hydralazine, there is evidence of increased renal blood flow and a maintenance of glomerular filtration rate. In some instances where control values were below normal, improved renal function has been noted after administration of hydralazine. However, as with any antihypertensive agent, hydralazine should be used with caution in patients with advanced renal damage.
Peripheral neuritis, evidenced by paresthesia, numbness, and tingling, has been observed. Published evidence suggests an antipyridoxine effect, and that pyridoxine should be added to the regimen if symptoms develop.
SPL UNCLASSIFIED SECTION
Laboratory Tests
Complete blood counts and antinuclear antibody titer determinations are indicated before and periodically during prolonged therapy with hydralazine even though the patient is asymptomatic. These studies are also indicated if the patient develops arthralgia, fever, chest pain, continued malaise, or other unexplained signs or symptoms.
A positive antinuclear antibody titer requires that the physician carefully weigh the implications of the test results against the benefits to be derived from antihypertensive therapy with hydralazine hydrochloride.
Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, and purpura, have been reported. If such abnormalities develop, therapy should be discontinued.
SPL UNCLASSIFIED SECTION
Drug Interactions
MAO inhibitors should be used with caution in patients receiving hydralazine.
When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and hydralazine injection are used concomitantly.
SPL UNCLASSIFIED SECTION
Carcinogenesis, Mutagenesis, Impairment of Fertility
In a lifetime study in Swiss albino mice, there was a statistically significant increase in the incidence of lung tumors (adenomas and adenocarcinomas) of both male and female mice given hydralazine continuously in their drinking water at a dosage of about 250 mg/kg per day (about 80 times the maximum recommended human dose). In a 2-year carcinogenicity study of rats given hydralazine by gavage at dose levels of 15, 30 and 60 mg/kg/day (approximately 5 to 20 times the recommended human daily dosage), microscopic examination of the liver revealed a small, but statistically significant, increase in benign neoplastic nodules in male and female rats from the high-dose group and in female rats from the intermediate-dose group. Benign interstitial cell tumors of the testes were also significantly increased in male rats from the high-dose group. The tumors observed are common in aged rats and a significantly increased incidence was not observed until 18 months of treatment. Hydralazine was shown to be mutagenic in bacterial systems (Gene Mutation and DNA Repair) and in one of two rats and one rabbit hepatocyte in vitro DNA repair studies. Additional in vivo and in vitro studies using lymphoma cells, germinal cells, and fibroblasts from mice, bone marrow cells from chinese hamsters and fibroblasts from human cell lines did not demonstrate any mutagenic potential for hydralazine.
The extent to which these findings indicate a risk to man is uncertain. While long-term clinical observation has not suggested that human cancer is associated with hydralazine use, epidemiologic studies have so far been insufficient to arrive at any conclusions.
SPL UNCLASSIFIED SECTION
Pregnancy
Teratogenic effects
Animal studies indicate that hydralazine is teratogenic in mice at 20 to 30 times the maximum daily human dose of 200 to 300 mg and possibly in rabbits at 10 to 15 times the maximum daily human dose, but that it is nonteratogenic in rats. Teratogenic effects observed were cleft palate and malformations of facial and cranial bones.
There are no adequate and well-controlled studies in pregnant women. Although clinical experience does not include any positive evidence of adverse effects on the human fetus, hydralazine should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.
SPL UNCLASSIFIED SECTION
Nursing Mothers
Hydralazine has been shown to be excreted in breast milk.
SPL UNCLASSIFIED SECTION
Pediatric Use
Safety and effectiveness in pediatric patients have not been established in controlled clinical trials, although there is experience with the use of hydralazine hydrochloride in children. The usual recommended parenteral dosage, administered intramuscularly or intravenously, is 1.7 to 3.5 mg/kg of body weight daily, divided into four to six doses.
ADVERSE REACTIONS
SPL UNCLASSIFIED SECTION
Adverse reactions with hydralazine hydrochloride are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug.
The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.
| Common: | Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris. |
| Less Frequent: | Digestive: constipation, paralytic ileus. Cardiovascular: hypotension, paradoxical pressor response, edema. Respiratory: dyspnea Neurologic: peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety. Genitourinary: difficulty in urination. Hematologic : blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly. Hypersensitive Reactions : rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and, rarely, hepatitis. Other : nasal congestion, flushing, lacrimation, conjunctivitis. |
To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
OVERDOSAGE
Acute Toxicity: No deaths due to acute poisoning have been reported.
Highest known dose survived: adults, 10 g orally.
Oral LD50 in rats: 173 and 187 mg/kg.
SPL UNCLASSIFIED SECTION
Signs and Symptoms
Signs and symptoms of overdosage include hypotension, tachycardia, headache, and generalized skin flushing.
Complications can include myocardial ischemia and subsequent myocardial infarction, cardiac arrhythmia, and profound shock.
SPL UNCLASSIFIED SECTION
Treatment
There is no specific antidote.
Support of the cardiovascular system is of primary importance. Shock should be treated with plasma expanders. If possible, vasopressors should not be given, but if a vasopressor is required, care should be taken not to precipitate or aggravate cardiac arrhythmia.
Tachycardia responds to beta blockers. Digitalization may be necessary, and renal function should be monitored and supported as required.
No experience has been reported with extracorporeal or peritoneal dialysis.
DOSAGE AND ADMINISTRATION
When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein. Hydralazine hydrochloride injection should be used only when the drug cannot be given orally. The usual dose is 20 to 40 mg, repeated as necessary.
Certain patients (especially those with marked renal damage) may require a lower dose. Blood pressure should be checked frequently. It may begin to fall within a few minutes after injection, with the average maximal decrease occurring in 10 to 80 minutes. In cases where there has been increased intracranial pressure, lowering the blood pressure may increase cerebral ischemia. Most patients can be transferred to oral hydralazine hydrochloride within 24 to 48 hours.
The product should be used immediately after the vial is opened. It should not be added to infusion solutions. Hydralazine hydrochloride injection may discolor upon contact with metal; discolored solutions should be discarded.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Discard unused portion.
HOW SUPPLIED
Hydralazine Hydrochloride Injection, USP is a colorless solution and is supplied as follows:
| NDC | Hydralazine Hydrochloride for Injection, USP (20 mg per mL) | Package Factor |
| 71288-205-02 | 20 mg per mL Single-Dose Vial | 25 vials per carton |
Storage
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Sterile, Nonpyrogenic.
The container closure is not made with natural rubber latex.
meitheal®
Mfd. for Meitheal Pharmaceuticals
Chicago, IL 60631 (USA)
©2025 Meitheal Pharmaceuticals Inc.
Mfd. by Kindos Pharmaceuticals Co., Ltd.
Chengdu, China 611731
Product of India
October 2025
LB-513-V1
Principal Display Panel – hydrALAZINE Hydrochloride Injection, USP 20 mg per mL Vial
NDC 71288-205-01
Rx Only
hydrALAZINE Hydrochloride Injection, USP
20 mg per mL
For Intramuscular or Intravenous Use
1 mL Single-Dose Vial
Principal Display Panel – hydrALAZINE Hydrochloride Injection, USP 20 mg per mL Carton
NDC 71288-205-02
Rx Only
hydrALAZINE Hydrochloride Injection, USP
20 mg per mL
For Intramuscular or Intravenous Use
25 x 1 mL Single-Dose Vials
DailyMed RxNorm Mappings#
DailyMed Pharmacologic Classes#
| Class | Version | Type | Effective |
|---|---|---|---|
| HYDRALAZINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
Product Linked Resources#
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | DataBar Limited | (01)00371288205013 | GTIN-14: 00371288205013 GTIN-12: 371288205013 UPC-A: 371288205013 EAN-13: 0371288205013 GTIN storage (14 digits): 00371288205013 | 20mg-vial-v3.jpg |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| a3137695-e199-b3b3-2950-87a8ac429689 | Product name | 5 | 20260316 |
| e9ed2ee5-d109-4795-bffe-c3b047717749 | Product name | 2 | 20250107 |
| 0284f4a6-db58-dacf-18fe-da73f4aeea88 | Product name | 4 | 20180827 |
| 0ad8bdca-888e-00da-648b-6a4de854a167 | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71288-205-01 | HYDRALAZINE HYDROCHLORIDE | 1 mL in 1 VIAL, SINGLE-DOSE | INJECTION | 1 | 4 | |
| 71288-205-02 | HYDRALAZINE HYDROCHLORIDE | 25 in 1 CARTON | INJECTION | 25 | 4 |
Products#
Every source-derived product name is available through these pages.
- HYDRALAZINE HYDROCHLORIDE
- HYDRALAZINE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 71288-205 | 71288-205-01, 71288-205-02 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Hydralazine Hydrochloride | FD171B778Y | ACTIB |
Source Document#
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A217501-001 | HYDRALAZINE HYDROCHLORIDE | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A217501-001 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A217501-001 | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A217501-001 | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217501-001 | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217501-001 | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A217501-001 | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 | 6a471c1ec25d… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217501-001 | HYDRALAZINE HYDROCHLORIDE | 20MG/ML | INJECTABLE / INJECTION | AP | 2025-06-02 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A217501-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A217501-001 | AP | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A217501-001 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217501-001 | AP | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A217501-001 | AP | 1 | 6a471c1ec25d… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A217501-001 | AP | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| HYDRALAZINE HYDROCHLORIDE | HYDRALAZINE HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | f3c806a4-b971-421c-bcb9-9979c6d7aaec | 2026-02-27 | Warnings, Adverse reactions | 71288-205-02 71288-205-01 71288-205 71288020502 71288020501 2926d221-0ca5-4379-ac53-773051ec5c79 f3c806a4-b971-421c-bcb9-9979c6d7aaec |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.